Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duloxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 0.95 |
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.95 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.95 |
| ▸ | MLNR | O43193 | 1/20 | 0.95 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.95 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.95 |
| ▸ | HTR1A | P08908 | 1/20 | 0.95 |
| ▸ | GAA | P10253 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.95 |
| ▸ | DRD2 | P14416 | 1/20 | 0.95 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.95 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.95 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 1/20 | 0.95 |
| ▸ | HTR2C | P28335 | 1/20 | 0.95 |
| ▸ | MC4R | P32245 | 1/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duloxetine SCHEMBL3398599 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL1200511 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL30197067 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL29355040 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL10036575 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3803 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL8291 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL30003730 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL647773 | 0.96 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL3901869 | 0.96 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058272-A1 | STABLE PARENTERAL FORMULATIONS OF DULOXETINE | LEIUTIS PHARMACEUTICALS LLP (IN) | 2024-02-22 | — | — | US | claimed |
| US-20220409544-A1 | STABLE PARENTERAL FORMULATIONS OF DULOXETINE | LEIUTIS PHARMACEUTICALS LLP (IN) | 2022-12-29 | — | — | US | claimed |
| WO-2021100030-A1 | STABLE PARENTERAL FORMULATIONS OF DULOXETINE | LEIUTIS PHARMACEUTICALS PRIVATE LIMITED (IN) | 2021-05-27 | — | — | WO | claimed |
| US-8658400-B2 | Biocatalysts for manufacturing duloxetine alcohol | BASF SE (DE) | 2014-02-25 | — | — | US | claimed |
| CN-102317450-A | IMPROVED BIOCATALYSTS FOR MANUFACTURING DULOXETINE ALCOHOL | BASF SE | 2012-01-11 | — | — | CN | claimed |
| US-20110250655-A1 | Biocatalysts For Manufacturing Duloxetine Alcohol | BASF SE (DE) | 2011-10-13 | — | — | US | claimed |
| US-20240058272-A1 | STABLE PARENTERAL FORMULATIONS OF DULOXETINE | LEIUTIS PHARMACEUTICALS LLP (IN) | 2024-02-22 | — | — | US | disclosed |
| US-20220409544-A1 | STABLE PARENTERAL FORMULATIONS OF DULOXETINE | LEIUTIS PHARMACEUTICALS LLP (IN) | 2022-12-29 | — | — | US | disclosed |
| US-8658400-B2 | Biocatalysts for manufacturing duloxetine alcohol | BASF SE (DE) | 2014-02-25 | — | — | US | disclosed |
| US-8658400-B2 | Biocatalysts for manufacturing duloxetine alcohol | BASF SE (DE) | 2014-02-25 | — | — | US | disclosed |
| US-8658400-B2 | Biocatalysts for manufacturing duloxetine alcohol | BASF SE (DE) | 2014-02-25 | — | — | US | disclosed |
| US-8455223-B2 | Reducing substituted alkanones such as 3-methylamino-1-(2-thienyl)-propan-1-one; biosynthesis; expression cassettes; host cells; for production of duloxetine | BASF SE (DE) | 2013-06-04 | — | — | US | disclosed |
| CN-102317450-A | IMPROVED BIOCATALYSTS FOR MANUFACTURING DULOXETINE ALCOHOL | BASF SE | 2012-01-11 | — | — | CN | disclosed |
| WO-2011009849-A2 | METHOD FOR PREPARING OPTICALLY ACTIVE HYDROXY ACID ESTERS | BASF SE (DE) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010079068-A1 | IMPROVED BIOCATALYSTS FOR MANUFACTURING DULOXETINE ALCOHOL | BASF SE (DE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079068-A1 | IMPROVED BIOCATALYSTS FOR MANUFACTURING DULOXETINE ALCOHOL | BASF SE (DE) | 2010-07-15 | — | — | WO | disclosed |
| CN-101321876-A | Enzymatic reduction for producing optically active alcohols | BASF AG (DE) | 2008-12-10 | — | — | CN | disclosed |
| US-20080220484-A1 | Novel Dehydrogenases, the Derivatives thereof, and Method for the Production of Optically Active Alkanols | BASF AKTIENGESELLSCHAFT (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20060211099-A1 | L-carnitin dehydrogenases, their derivatives and method for producing substituted (s) alkanols | BASF AKTIENGESELLSCHAFT (DE) | 2006-09-21 | — | — | US | disclosed |
| CN-1771323-A | L-carnitin dehydrogenases, their derivatives and method for producing substituted (s) alkanols | BASF AG (DE) | 2006-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080220484-A1 | Novel Dehydrogenases, the Derivatives thereof, and Method for the Production of Optically Active Alkanols | ALDH7A1, ALDH3A1, ADH5 | SLC6A2 3802/4885SLC6A4 3740/4885SLC6A3 3041/4885 |
| US-20110250655-A1 | Biocatalysts For Manufacturing Duloxetine Alcohol | ADH5, ADH1A, ADH1C | SLC6A2 102/4885SLC6A4 118/4885SLC6A3 245/4885 |
| US-20060211099-A1 | L-carnitin dehydrogenases, their derivatives and method for producing substituted (s) alkanols | ALDH7A1, ALDH3A1, AMPD3 | SLC6A2 3400/4885SLC6A4 3990/4885SLC6A3 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.